Search Results
Your search for The ,The matches 34685 pages
Showing 32851 - 32900BRAF Inhibitor Vemurafenib Plus MEK inhibitor Cobimetinib vs Vemurafenib Alone in Previously Untreated BRAF-Mutant Advanced Melanoma
In a phase III trial reported in The New England Journal of Medicine, Larkin and colleagues found that the combination of the BRAF inhibitor vemurafenib (Zelboraf) and the MEK inhibitor cobimetinib improved response rate and progression-free survival compared with vemurafenib alone in...
Absence of Residual Thrombosis After 6 Months of Low–Molecular Weight Heparin Indicates Low Risk for Recurrent Cancer-Related Deep-Vein Thrombosis
In an Italian study (Cancer-DACUS) reported in the Journal of Clinical Oncology, Napolitano et al found that patients with no residual vein thrombosis after 6 months of low–molecular weight heparin for a first episode of cancer-related deep-vein thrombosis of the lower limbs had low risk for...
ASCO Endorses AUA/ASTRO Guideline on Adjuvant and Salvage Radiotherapy After Prostatectomy
The American Society of Clinical Oncology (ASCO) today issued an endorsement of the American Urological Association (AUA)/American Society for Radiation Oncology (ASTRO) guideline on the use of adjuvant and salvage radiotherapy after prostatectomy, which was based on a systematic review of medical...
Crizotinib Highly Active in ROS1-Rearranged NSCLC
In a study reported in The New England Journal of Medicine, Shaw et al found that crizotinib (Xalkori) produced a high response rate in patients with ROS1-rearranged non–small cell lung cancer (NSCLC). Chromosomal rearrangements in ROS1, which encodes the proto-oncogene receptor tyrosine...
Scoring to Predict Individual Risk of Heart Failure Among Childhood Cancer Survivors
In a study reported in the Journal of Clinical Oncology, Chow and colleagues developed risk scoring that can identify likelihood of heart failure among childhood cancer survivors. Study Details The study involved survivors in the Childhood Cancer Survivor Study (CCSS) free of significant...
Similar Local Tumor Recurrence Rates With Hypofractionated vs Conventional Radiotherapy for Ductal Carcinoma in Situ
In patients with ductal carcinoma in situ of the breast who underwent breast-conserving surgery, hypofractionated radiation therapy was not significantly associated with an increased risk of any local recurrence when compared with conventional radiation therapy, according to the study findings...
Protein Linked With HPV-Positive Head and Neck Cancer May Lead to More Effective Therapies for the Disease
Scientists investigating the molecular mechanism of the protein p16 in cisplatin-treated head and neck cancer cells have found that the drug is able to kill the malignant cells by interacting with the protein gigaxonin. Although p16 is commonly produced in human papillomavirus (HPV)-positive...
Rewiring Cell Metabolism Slows Colorectal Cancer Growth
Cancer is an unwanted experiment in progress. As the disease advances, tumor cells accumulate mutations, eventually arriving at ones that give them the insidious power to grow uncontrollably and spread. Distinguishing drivers of cancer from benign mutations open opportunities for developing...
Gemcitabine-Based Treatment Yields Similar Response Rates, Less Toxicity Than DHAP Before Stem Cell Transplant for Relapsed/Refractory Lymphoma
In the NCIC-CTG LY.12 study, a phase III international noninferiority trial reported in the Journal of Clinical Oncology, Crump and colleagues found that gemcitabine, dexamethasone, and cisplatin (GDP) was associated with a noninferior response rate and similar transplantation rate compared with...
Analysis Suggests 70-Gene Signature Strategy Is Not Cost-Effective in Adjuvant Decisions in Patients With Node-Negative Breast Cancer
In a French analysis reported in the Journal of Clinical Oncology, Bonastre and colleagues found that use of the 70-gene signature (MammaPrint) was unlikely to be cost-effective in deciding whether to administer adjuvant therapy in patients with node-negative breast cancer. Use of Adjuvant! Online...
Registry Data Reveals Sustained Local Control With Minimal Side Effects for Medically Inoperable, Early-Stage Lung Cancer Patients Receiving SBRT
Analysis of data from an institutional patient registry on stereotactic body radiotherapy (SBRT) indicates excellent long-term, local control in 79% of tumors for medically inoperable, early-stage lung cancer patients treated with the procedure from 2003 to 2012, according to research presented at...
Postoperative Radiation Therapy Improves Overall Survival for Patients With Resected Pathologic N2 Non–Small Cell Lung Cancer
Patients who received postoperative radiation therapy lived an average of 4 months longer when compared to the patients who had the same disease site, tumor histology, and treatment criteria and who did not receive postoperative radiotherapy, according to research presented at the 2014 Chicago ...
Cancer Leaders Call for Congress to Act Quickly in 2015 to Reinvigorate Cancer Innovation in the United States
Even before the next Congress is formally elected, a national group of health-care stakeholders called the Cancer Innovation Coalition (CIC) went to Capitol Hill today to call for early legislative and regulatory action in 2015 that will reinvigorate cancer innovation in the United States. The...
Predictive Ability of CT Screen-Detected Nodule Volume, Diameter, and Volume-Doubling for Lung Cancer in NELSON Trial
The Dutch and Belgian NELSON trial is assessing the effect of increasing interval low-dose computed tomography (CT) screening for lung cancer on lung cancer mortality. In an analysis among screened Dutch participants reported in Lancet Oncology, Horeweg and colleagues identified screen-detected...
Performance of Lung Cancer Low-Dose CT Screening With Increasing Screening Interval in NELSON Trial
The Dutch and Belgian NELSON trial is assessing the effect of increasing interval low-dose computed tomography (CT) screening for lung cancer on lung cancer mortality. In an analysis of screening test performance among Dutch participants reported in Lancet Oncology, Horeweg and colleagues found...
Molecular Tumor Markers Could Reveal New Therapeutic Targets for Lung Cancer Treatment
Analysis of 607 small cell lung cancer (SCLC) tumors and neuroendocrine tumors identified common molecular markers among both groups that could reveal new therapeutic targets for patients with similar types of lung cancer, according to research presented at the 2014 Chicago Multidisciplinary...
No Difference in Survival Rates in Patients With Lung Adenocarcinoma In Situ vs Minimally Invasive Adenocarcinoma
Lung cancer patients with minimally invasive adenocarcinoma have similar, positive 5-year disease-free survival and overall survival rates as patients with adenocarcinoma in situ, according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology (Abstract...
Medicare Costs Analysis Indicates Need for Decreasing Use of Biopsies as Diagnosis Tool for Lung Cancer
Biopsies were found to be the most costly tool prescribed in lung cancer diagnosis, according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology (Abstract 103). The study examined the utilization rates and estimated the Medicare costs of the lung...
Patients at High-Risk for Lung Cancer Are More Likely to Receive Screening When Primary Care Provider Is Familiar With Guideline Recommendations
Patients at high-risk for developing lung cancer are more likely to receive low-dose computed tomography (CT) screening when their primary care provider is familiar with guideline recommendations for low-dose CT screening for lung cancer, according to research presented today at the 2014 Chicago...
Oncology Advances Included in Cleveland Clinic's Top 10 Medical Innovations List for 2015
Antibody-drug conjugates, checkpoint inhibitors, and single-dose intraoperative radiation therapy for breast cancer were included in the Cleveland Clinic's Ninth Annual Top 10 Medical Innovations List released earlier today. The list identifies those advances likely to have a major impact on...
ALSYMPCA Subgroup Analysis: Radium-223 Survival Benefit Irrespective of Prior Docetaxel in Castration-Resistant Prostate Cancer With Bone Metastases
The phase III ALSYMPCA trial showed that radium-223 (Xofigo) increased overall survival vs placebo patients with castration-resistant prostate cancer and symptomatic bone metastases. In a prespecified subgroup analysis reported in The Lancet Oncology, Hoskin et al found that overall survival...
Higher Levels of Lecithin Retinol Acyltransferase Hypermethylation May Correlate With Earlier Stage of Colorectal Cancer
Compared with normal colorectal mucosae, nearly half of colorectal tumors showed medium-to-high levels of lecithin retinol acyltransferase (LRAT) hypermethylation, according to the results of a study reported by Cheng et al in Medical Oncology. This finding was noted more frequent in earlier tumor...
New Research Shows Association of Kidney Cancer With Use of Aristolochic Acid
New research by the international Cancer Genomics of the Kidney consortium (CAGEKID) reveals an important connection between kidney cancer and exposure to aristolochic acid, an ingredient in some herbal remedies. The findings, published by Scelo et al in Nature Communications, have important...
Language and Communication Cognitive Complaints Worsen After Initiation of Endocrine Therapy in Early-Stage Breast Cancer
Data suggest that cancer treatment puts patients at risk of cognitive impairment and that many patients exhibit impairment prior to treatment. In an observational cohort study reported in the Journal of Clinical Oncology, Ganz et al found that language and communication cognitive complaints were...
Topical Cidofovir and Imiquimod Active in Treating Vulval Intraepithelial Neoplasia
In a UK phase II trial reported in The Lancet Oncology, Tristram et al found that topical cidofovir and topical imiquimod were active in the treatment of vulval intraepithelial neoplasia, suggesting that such treatment may constitute an alternative to surgery. Study Details In the open-label...
Increased Prediagnosis BMI Associated With Increased Risk of Second Obesity-Associated Cancers in Colorectal Cancer Survivors
Overweight and obesity are associated with increased risk of primary colorectal cancer, as well as increased risk of breast, endometrial, esophageal, pancreatic, and kidney cancers. In a pooled analysis of prospective cohort studies reported in the Journal of Clinical Oncology, Gibson et al found...
CLEOPATRA Analysis Shows That HER2 Is Sole Marker Suitable for Selection of Pertuzumab/Trastuzumab-Based Treatment in Metastatic Breast Cancer
In an analysis in the CLEOPATRA trial population reported in the Journal of Clinical Oncology, Baselga et al found that HER2 was the only biomarker suitable for use in selecting patients for first-line pertuzumab (Perjeta)/trastuzumab (Herceptin)-based treatment in patients with HER2-positive...
Survey Finds High Rates of Burnout Among Palliative Care Physicians, With Over 50% Predicted to Leave the Field in 10 Years
Physician burnout in palliative care is higher—over 62%—than the burnout rate reported in medical oncology—45%—according to a large survey of over 1,200 hospice and palliative care clinicians. The factors contributing to professional burnout severity included younger age,...
Chest Radiation to Treat Childhood Cancer Increases Patients’ Risk of Developing Breast Cancer
A new study has found that patients who received chest radiation for Wilms tumor, a rare childhood cancer, face an increased risk of developing breast cancer later in life due to their radiation exposure. Reported by Lange et al in Cancer, the findings suggest that cancer screening guidelines might ...
Long-Term Overall Survival Benefit of Adding Trastuzumab to Adjuvant Chemotherapy in Early-Stage HER2-Positive Breast Cancer
Earlier planned joint analyses of outcomes in the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-31 trial and North Central Cancer Treatment Group (NCCTG) N9831 trial showed that adding trastuzumab (Herceptin) to adjuvant chemotherapy improved disease-free survival and overall...
Overuse and Underuse of Recommended Imaging for Lung Cancer Staging in National VA Cohort
In a study reported in the Journal of Clinical Oncology, Backhus et al found that imaging guideline recommendations for staging of locally advanced lung cancer were often not followed in a national Veterans Affairs (VA) cohort. Study Details The study involved 3,808 patients with stage IIB, IIIA, ...
Single Nucleotide Polymorphisms in Thrombomodulin Gene Predict Mortality in Patients With Graft-vs-Host Disease
The pathophysiology of steroid refractoriness in graft-vs-host disease in allogeneic stem cell transplantation is not completely understood, although there is evidence that endothelial cell stress, which involves endothelial thrombomodulin, plays a role. In a study reported in the Journal of...
FDA Grants Breakthrough Therapy Designation Pembrolizumab in Advanced Non–Small Cell Lung Cancer
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to the anti–PD-1 therapy pembrolizumab (Keytruda) for the treatment of patients with epidermal growth factor receptor (EGFR) mutation–negative, and anaplastic lymphoma kinase (ALK)...
Low Mitotic Count Is an Independent Predictor of Survival in Women With Recurrent Uterine Leiomyosarcoma
Although low mitotic count, surgery, and disease-free interval of more than 6 months were associated with improved survival in women with recurrent or persistent uterine leiomyosarcoma, only low number of mitoses was identified as an independent predictor of survival post relapse, according to...
Genomic Sequencing More Efficient in Predicting Breast Cancer Risk Than Previously Thought
Using genomic sequencing data on all currently known genetic alterations in breast cancer, it is possible to identify a woman’s genetic risk for the disease, and this approach can bring greater gains in disease prevention than previously estimated, according to a study reported by Sieh et al...
No Progression-Free Survival Benefit of Dacomitinib vs Erlotinib Overall or in KRAS Wild-Type Disease in Pretreated Advanced NSCLC
In a phase III ARCHER 1009 trial reported in The Lancet Oncology, Ramalingam et al found no progression-free survival benefit of the irreversible pan-HER tyrosine kinase inhibitor dacomitinib vs erlotinib among all patients with pretreated non–small cell lung cancer (NSCLC) or among those...
No Survival Benefit With Pan-HER Tyrosine Kinase Inhibitor Dacomitinib vs Placebo in Pretreated Advanced NSCLC
In the phase III NCIC CTG BR.26 Trial reported in The Lancet Oncology, Ellis et al found that treatment with the irreversible pan-HER tyrosine kinase inhibitor dacomitinib was not associated with an overall survival benefit compared with placebo in patients with pretreated advanced or...
Regional Hepatopancreaticobiliary Surgical Program Improves Care in VA System
In a retrospective cohort study reported in JAMA Surgery, Lau et al found that implementation of a multidisciplinary hepatopancreaticobiliary surgical program in a Veterans Affairs (VA) health-care region resulted in improved care and outcomes. The study involved analysis of practices and outcomes ...
Loss of Y Chromosome Associated With Higher Mortality and Risk of Cancer in Men
Age-related loss of the Y chromosome from blood cells, a frequent occurrence among elderly men, is associated with elevated risk of various cancers and earlier death, according to research presented at the American Society of Human Genetics 2014 Annual Meeting in San Diego (Abstract 295). This...
Higher Alkylating Agent Exposure Associated With Impaired Spermatogenesis in Adult Survivors of Childhood Cancer
In a study in the St. Jude Lifetime Cohort Study population reported in The Lancet Oncology, Green et al found that increasing alkylating agent exposure was associated with impaired spermatogenesis in adult male survivors of childhood cancer who did not undergo radiation therapy as part of their...
Oral Rivaroxaban Has Efficacy Similar to Enoxaparin Plus Vitamin K Antagonist in Preventing Recurrent Venous Thromboembolism
In a subgroup analysis of the pooled results of the EINSTEIN-DVT and EINSTEIN-PE trials reported in The Lancet Haematology, Prins et al found that the recurrence rate for venous thromboembolism in cancer patients receiving anticoagulant therapy with oral rivaroxaban (Xarelto) was similar to that in ...
Many Insured Patients Alter Their Lifestyles and Medical Care to Cope With Cancer Treatment Costs
A small nationwide survey finds many insured patients are changing their lifestyle and medical care in the face of treatment-related financial burdens. In fact, more than one-third adopted medical care–altering strategies, with younger and lower-income patients being more likely to alter...
One-Third of U.S. Cancer Survivors May Be Experiencing Financial or Work-Related Hardship
New results from a survey of nearly 1,600 cancer survivors indicate a high prevalence of financial and work-related difficulties: 27% reported at least one financial problem (eg, debt, bankruptcy), and 37% reported having to modify work plans, such as taking extended time off or delaying...
‘Smart Technology’ System for Home Hospice Symptom Management and Care Helps Both Patients With Cancer and Family Caregivers
Early findings from a study of 319 families suggest that use of an innovative, telephone-based symptom monitoring and coaching system during home hospice care leads to significantly decreased patient symptoms in the final weeks of life. The findings will be presented at the 2014 Palliative Care in...
Partnership Between Medical Oncologists and Palliative Care Specialists Improves Outcomes at an Inpatient Oncology Unit
First evaluation of a pioneering “co-rounding” partnership between medical oncologists and palliative care specialists at Duke University Medical Center shows improvements in both health system–related and patient-related outcomes. The first year of the new partnership—set...
First-Line FOLFIRI Improves Time to Treatment Failure and Is Better Tolerated vs ECX in Advanced Gastric Cancer
In a phase III French Intergroup trial reported in the Journal of Clinical Oncology, Guimbaud et al found that FOLFIRI (fluorouracil [5-FU], leucovorin, and irinotecan) significantly prolonged time to treatment failure compared with ECX (epirubicin, cisplatin, and capecitabine) in first-line...
Blood Biomarker May Detect Lung Cancer
A new study shows that patients with stage I to III non–small cell lung cancer have different metabolite profiles in their blood than those of patients who are at risk but do not have lung cancer. The study abstract was released today in an online supplement to the journal CHESTand will be...
Newly Discovered Molecular-Level Mechanism May Increase the Growth of Breast Cancer Cells
Researchers at VTT Technical Research Centre of Finland, the University of Turku, Finland, and the University of Oslo, Norway, have discovered a previously unknown molecular-level mechanism that may partly explain the increased growth of cancer cells. The study, published in the British Journal of...
Study Finds Increased Expression of NQO1 in Non–Small Cell Lung Cancer Patients With KRAS Mutations
In smokers with non–small cell lung cancer (NSCLC), the relationship between KRAS mutations and NQO1 may be of future therapeutic value, according to the study findings presented by Yilmaz et al in the International Journal of Environmental Research and Public Health. The researchers...
ASCO Issues Clinical Expert Statement on Cancer Survivorship Care Planning
Efforts at implementing survivorship care plans have met with limited success in oncology practice, in part due to the time required to complete survivorship care plans, lack of role clarity, and lack of reimbursement for time to complete the documents. In response, ASCO convened a Survivorship...
